Skip to main
IMNN
IMNN logo

Imunon Inc (IMNN) Stock Forecast & Price Target

Imunon Inc (IMNN) Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Imunon Inc. has demonstrated promising clinical results from its Phase II trial of IMNN-001, with many patients exhibiting sustained positive outcomes that have resulted in improved hazard ratios and overall survival metrics. The ongoing development of IMNN-001, which has shown a significant median overall survival advantage and a favorable safety profile, positions the company favorably as it prepares to initiate a pivotal Phase 3 trial, with recent FDA meetings indicating strong alignment on trial design. The continued strengthening of the clinical data supports the potential of Imunon's DNA-mediated immunotherapy platform, enhancing confidence in its prospects for successful market entry and patient impact.

Bears say

Imunon Inc's stock faces a negative outlook due to concerns regarding delayed regulatory approvals for its therapies, with potential European approval staggered by three years behind the anticipated U.S. timeline, suggesting a slower market entry and revenue generation. Despite a year-over-year decline of 9% in operating expenses attributed to effective cost management, the company's financial health may still be challenged by the lengthy path to commercialization of its lead product, IMNN-001, in treating ovarian cancer. Furthermore, uncertainties surrounding the clinical outcomes and market acceptance of its COVID-19 booster vaccine, IMNN-101, also contribute to potential risks impacting future financial performance and investor confidence.

Imunon Inc (IMNN) has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Imunon Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Imunon Inc (IMNN) Forecast

Analysts have given Imunon Inc (IMNN) a Strong Buy based on their latest research and market trends.

According to 4 analysts, Imunon Inc (IMNN) has a Strong Buy consensus rating as of Jul 23, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $18.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $18.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Imunon Inc (IMNN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.